Edition:
India

Sorrento Tech Inc (ROKA.OQ)

ROKA.OQ on NASDAQ Stock Exchange Global Market

1.00USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.00
Open
$0.99
Day's High
$1.03
Day's Low
$0.99
Volume
14,064
Avg. Vol
172,958
52-wk High
$6.20
52-wk Low
$0.66

Summary

Name Age Since Current Position

Paul Thomas

61 2017 Chairman of the Board

Mary Duseau

52 2017 President, Chief Executive Officer, Secretary, Director

Lars Boesgaard

47 2015 Chief Financial Officer, Vice President, Treasurer

Nicholas Valeriani

60 2015 Director

Michael Doyle

67 2010 Independent Director

David McGirr

62 2013 Independent Director

Biographies

Name Description

Paul Thomas

Mr. Paul G. Thomas is Chairman of the Board of the Company. He was President, Chief Executive Officer, Secretary of the Company. From September 2008 to September 2009, Mr. Thomas was an independent consultant. Previously, from October 1998 until September 2008, he served as chairman, chief executive officer, and president of LifeCell Corporation, a publicly traded company focused on developing and marketing reconstructive surgical products, which was acquired by Kinetic Concepts, Inc., Mr. Thomas previously served as a member of the board of directors of Orthovita, Inc., a publicly traded orthobiologics and biosurgery company, until its sale in June 2011 to Stryker Corporation (NYSE: SYK). Mr. Thomas received his Master of Business Administration from Columbia University, and completed his postgraduate studies in chemistry at the University of Georgia. He received his Bachelor of Science in Chemistry from St. Michael’s College. In addition to Mr. Thomas’ extensive leadership experience with public companies in the life sciences industry, .

Mary Duseau

Ms. Mary Duseau is President, Chief Executive Officer, Secretary, Director of the Company. She was Senior Vice President, Chief Commercial Officer of Company. From October 2012 until January 2015, Ms. Duseau held various positions at Andor Technology plc (“Andor”), a division of Oxford Instruments plc and leader in the global scientific digital camera market, and since February 2014 has served as Global Sales Director at Andor where she oversaw the company’s global sales organization. Prior to joining Andor, Ms. Duseau held various sales and management roles of increasing responsibility with PerkinElmer, Inc. (NYSE: PKI) from 2000 through September 2012, including the position of Vice-President Sales & Marketing, Bio-discovery, from 2008 to September 2012, where she led the sales and marketing of the company’s life science tools business. Ms. Duseau received her Bachelor of Science in Biochemistry with a minor in Neuroscience from the University of Massachusetts, Amherst.

Lars Boesgaard

Mr. Lars Boesgaard is Chief Financial Officer, Vice President, Treasurer of the Company. He was Vice President - Finance of Roka Bioscience, Inc. He has more than 16 years of experience in financial management, obtained primarily in the life sciences industries. Previously he was Vice President of Finance at Insulet Corporation. Before to that, he served as Senior Director of Financial Services for Alexion Pharmaceuticals, Inc. Mr. Boesgaard began his career holding various finance positions at Novo Nordisk A/S in Denmark and Japan. He earned a Bachelor of Science in Business Administration from Copenhagen Business School and a Master of Business Administration from the Richard Ivey School of Business at Western University in Ontario, Canada.

Nicholas Valeriani

Mr. Nicholas J. Valeriani is Director of the Company. Mr. Valeriani has been the Chief Executive Officer of the Gary and Mary West Health Institute.Mr. Valeriani has announced plans to retire from the organization's chief executive position, effective September 3, 2015 , however he will remain on the Institute's board of directors and will join the Gary and Mary West Health Policy Center's board. Prior to joining West Health, Mr. Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee. Currently, Mr. Valeriani serves on the boards of directors of Robert Wood Johnson University Hospital, Edwards Lifesciences Corporation and the Center for Medical Interoperability. Mr. Valeriani has a master's degree in business administration from Rutgers University , Graduate School of Management, and a bachelor's degree in industrial engineering from Rutgers University, College of Engineering .

Michael Doyle

Dr. Michael P. Doyle, Ph.D., is an Independent Director of the Company, since March 2010. Dr. Doyle has served as a Regent’s Professor of Food Microbiology and Director of the Center for Food Safety at the University of Georgia since March 1993. He is an active researcher in the area of food safety and security and works closely with the food industry, government agencies, and consumer groups on issues related to the microbiological safety of foods. He serves on food safety committees of many scientific organizations and has served as a scientific advisor to many groups, including the World Health Organization, the Institute of Medicine, the National Academy of Science-National Research Council, the International Life Sciences Institute-North America, the Food and Drug Administration, the U.S. Department of Agriculture, the U.S. Department of Defense, and the U.S. Environmental Protection Agency. He is a Fellow of the American Academy of Microbiology, the International Association for Food Protection and the Institute of Food Technologists, and is a member of the Institute of Medicine of the National Academies. We believe that Dr. Doyle’s extensive experience in the food safety industry, including as an advisor to agencies that regulate food safety, qualifies him to serve as a member of our board of directors.

David McGirr

Mr. David W. J. McGirr is an Independent Director of the Company, since December 2013. Mr. McGirr has served as a senior advisor of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a biopharmaceutical company focused on products for the acute care environment, since March 2013, and as senior vice president and chief financial officer from 2002 to March 2013. Prior to Cubist, Mr. McGirr was the president and chief operating officer of hippo inc, a privately-held internet technology company, and served as a member of their board of directors. Prior to hippo, Mr. McGirr was the president, and also served as chief executive officer, of GAB Robins North America, Inc., a risk management company. Prior to that, Mr. McGirr served in various positions within the S.G. Warburg Group, an investment bank, ultimately serving as chief financial officer, chief administrative officer and managing director of its subsidiary S.G. Warburg & Co., Inc. Mr. McGirr currently serves as a member of the board of directors and chairman of the audit committee of each of Insmed Incorporated (NASDAQ CM: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases, and Relypsa, Inc. Mr. McGirr received a B.Sc. in Civil Engineering from the University of Glasgow and an M.B.A. from the Wharton School at the University of Pennsylvania.

Basic Compensation

Name Fiscal Year Total

Paul Thomas

722,479

Mary Duseau

515,122

Lars Boesgaard

346,260

Nicholas Valeriani

--

Michael Doyle

--

David McGirr

--
As Of  31 Dec 2016

Options Compensation